Key result
Sacubitril/valsartan reduces NT-proBNP by ~56% vs ACEI/ARB in acute heart failure with high blood volume.
Why the study?
Whether estimated total blood volume is associated with heterogeneity in NT-proBNP response to sacubitril/valsartan in acute heart failure remains uncertain.
Does sacubitril/valsartan improve NT-proBNP reduction compared to ACEI/ARB in acute heart failure patients stratified by estimated total blood volume?
RCT (n=372)
Does sacubitril/valsartan improve NT-proBNP reduction compared to ACEI/ARB in acute heart failure patients stratified by estimated total blood volume?
Higher estimated total blood volume is associated with greater NT-proBNP reduction after sacubitril/valsartan compared to ACEI/ARB in acute heart failure, particularly in those with LVEF ≥40%.
Answers are grounded in this paper and cite their sources.
Estimated TBV may identify heterogeneity in NT-proBNP response to Sac/Val in AHF; hypothesis-generating and requires prospective validation.
BACKGROUND: Sacubitril/valsartan (Sac/Val) reduces N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in acute heart failure (AHF), particularly in patients with reduced ejection fraction. However, whether estimated total blood volume (TBV), calculated using anthropometric equations, is associated with heterogeneity in biomarker response remains uncertain. METHODS: This post hoc exploratory sub-analysis of the PREMIER randomized trial evaluated whether baseline estimated TBV was associated with heterogeneity in NT-proBNP reduction after Sac/Val compared with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) therapy. Estimated TBV was calculated using validated anthropometric equations and dichotomized at the median (4.05 L). Patients were further stratified by left ventricular ejection fraction (LVEF <40% vs. ≥40%). The primary endpoint was the proportional change in NT-proBNP from baseline to Week 8. RESULTS: Among 376 patients, 372 with baseline estimated TBV data were analyzed. In the high TBV group, Sac/Val was associated with greater NT-proBNP reduction than ACEI/ARB (-56% vs. -32%; ratio of change, 0.67; 95% confidence interval, 0.53-0.84; P=0.001), whereas no significant difference was observed in the low TBV group (P for heterogeneity=0.063). In patients with LVEF <40%, Sac/Val was associated with greater NT-proBNP reduction in both TBV groups. In patients with LVEF ≥40%, Sac/Val was associated with greater NT-proBNP reduction in the high TBV group, whereas the point estimate in the low TBV group numerically favored ACEI/ARB. CONCLUSIONS: In this exploratory post hoc analysis, higher estimated TBV was associated with greater NT-proBNP reduction after Sac/Val, particularly among patients with LVEF ≥40%. These findings are hypothesis-generating and require external validation. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05164653; Japan Registry of Clinical Trials, jRCTs021210046.
No takes yet. Share an insight, caveat, or question.
Nogi et al. (2026) conducted an RCT in Acute heart failure (n=372). Sacubitril/valsartan vs. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) was evaluated on Proportional change in NT-proBNP from baseline to Week 8 (ratio of change 0.67, 95% CI 0.53-0.84, p=0.001). In acute heart failure patients with high estimated total blood volume, sacubitril/valsartan yielded greater NT-proBNP reduction than ACEI/ARB.
Synapse has enriched 10 related papers. Consider them for comparative context: